Novo Nordisk
Novo Nordisk is a Danish multinational pharmaceutical company that specializes in diabetes care and hormone replacement therapies. Founded in 1923, the company is known for its innovative insulin products and GLP-1 receptor agonists, such as Ozempic, which are used for managing diabetes and aiding in weight loss. Novo Nordisk has a strong commitment to research and development, particularly in the fields of diabetes, obesity, and hemophilia.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Denmark | 2 | 6.00 | 0.13% | +0% | 5,792,202 | 7,702 | $350,000 | 465$ |
| Canada | 1 | 5.00 | 0.06% | +0% | 38,005,238 | 23,431 | $1,700,000 | 1,048$ |
| Totals | 3 | 43,797,440 | 31,133 | $2,050,000 | 1,513$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Denmark:
Novo Nordisk is a pharmaceutical giant that has presented impressive financial results over the years.
8
Denmark:
Novo Nordisk experienced a historic drop in stock value.
4
Canada:
Novo Nordisk is the Danish drugmaker that produces Ozempic and Wegovy.
5
Switzerland:
Novo Nordisk is a major competitor in the obesity treatment market alongside Eli Lilly.
8
Monaco:
Novo Nordisk is mobilized to obtain reimbursement for their obesity medications as soon as possible.
7
Denmark:
Novo Nordisk has taken a new step towards maintaining its leading position in the market for treating severe obesity and diabetes.
8
Ecuador:
Novo Nordisk alerted about counterfeit diabetes medication.
7
Italy:
Novo Nordisk produces Ozempic and is also working on a pill for diabetes and obesity.
6
Argentina:
Novo Nordisk is the owner of the original Ozempic and has announced the arrival of Wegovy in Argentina.
6
Estonia:
Novo Nordisk's stock decreased by 1.3 percent.
5